MedCity News
JULY 30, 2023
As clinical psychologists, we talk about therapy as the gold standard. I’m not saying it isn’t, but if only a minority of people are getting it, we need to broaden our perspective.
PharmExec
JULY 30, 2023
Webinar Date/Time: Tue, Sep 12, 2023 10:00 AM EDT | 9:00 AM CT | 3:00 PM BST | 4:00 PM CEST
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
JULY 30, 2023
It’s never a question of whether a hospital will experience downtime — it’s a matter of when. Adopting the right downtime technology means hospitals can cut costs, reduce stress on staff and mitigate risk of cyberattack by automatically encrypting data to HIPAA standards.
Pharmaceutical Technology
JULY 30, 2023
Pelabresib is a small molecule commercialized by MorphoSys, with a leading Phase III program in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF).
MedCity News
JULY 30, 2023
For breast cancer, 20.5% of patients received a screening in the year prior to being on Medicare, compared to 30.4% in the first year of being on Medicare, according to an Epic Research report. For colorectal cancer, screening rates jumped from 6% in the year before being on Medicare to 11% in the first year of being on Medicare.
Pharmaceutical Technology
JULY 30, 2023
Pelabresib is a small molecule commercialized by MorphoSys, with a leading Phase III program in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF).
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
JULY 30, 2023
Gedeptin is a gene therapy commercialized by GeoVax Labs, with a leading Phase II program in Recurrent Head And Neck Cancer Squamous Cell Carcinoma.
MedCity News
JULY 30, 2023
In this month’s episode, we dive into some recent executive appointments occurring in the healthcare world, as well as layoffs affecting the industry. We also hear from Leslie Orne, who recently became the new CEO of Trinity Life Sciences, which provides consulting services and technology solutions to life sciences firms looking to commercialize their product.
Pharmaceutical Technology
JULY 30, 2023
Gedeptin is a gene therapy commercialized by GeoVax Labs, with a leading Phase II program in Recurrent Head And Neck Cancer Squamous Cell Carcinoma.
MedCity News
JULY 30, 2023
Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
JULY 30, 2023
Vamorolone is a small molecule commercialized by Catalyst Pharmaceuticals, with a leading Pre-Registration program in Duchenne Muscular Dystrophy.
Pharmaceutical Technology
JULY 30, 2023
Nirogacestat hydrobromide is a small molecule commercialized by SpringWorks Therapeutics, with a leading Pre-Registration program in Benign Tumor.
Pharmaceutical Technology
JULY 30, 2023
Vamorolone is a small molecule commercialized by Catalyst Pharmaceuticals, with a leading Pre-Registration program in Duchenne Muscular Dystrophy.
Pharmaceutical Technology
JULY 30, 2023
Nirogacestat hydrobromide is a small molecule commercialized by SpringWorks Therapeutics, with a leading Pre-Registration program in Benign Tumor.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
JULY 30, 2023
FPI-1434 is a monoclonal antibody conjugated commercialized by Fusion Pharmaceuticals, with a leading Phase II program in Endometrial Cancer.
Pharmaceutical Technology
JULY 30, 2023
PF-06480605 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Crohn's Disease (Regional Enteritis).
Pharmaceutical Technology
JULY 30, 2023
PF-06480605 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Crohn's Disease (Regional Enteritis).
Pharmaceutical Technology
JULY 30, 2023
CAP-1002 is a cell therapy commercialized by Nippon Shinyaku, with a leading Phase III program in Duchenne Muscular Dystrophy.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharmaceutical Technology
JULY 30, 2023
CAP-1002 is a cell therapy commercialized by Nippon Shinyaku, with a leading Phase III program in Duchenne Muscular Dystrophy.
Pharmaceutical Technology
JULY 30, 2023
BNT-321 is a monoclonal antibody commercialized by BioNTech, with a leading Phase II program in Metastatic Colorectal Cancer.
Pharmaceutical Technology
JULY 30, 2023
BNT-321 is a monoclonal antibody commercialized by BioNTech, with a leading Phase II program in Metastatic Colorectal Cancer.
Pharmaceutical Technology
JULY 30, 2023
Resiniferatoxin is a small molecule commercialized by Shionogi, with a leading Phase III program in Osteoarthritis Pain.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmaceutical Technology
JULY 30, 2023
BGB-3245 is a small molecule commercialized by SpringWorks Therapeutics, with a leading Phase II program in Solid Tumor.
Pharmaceutical Technology
JULY 30, 2023
Resiniferatoxin is a small molecule commercialized by Shionogi, with a leading Phase III program in Osteoarthritis Pain.
Expert insights. Personalized for you.
98 
Let's personalize your content